DKBmed Radio

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety? Join us, as guest host Dr. Cole Harrington from the Ohio State University explores thes...

What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients? Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast i...

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should c...

Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services? These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International He...

Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients? Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these top...

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for...

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?   These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this  e MultipleSclero...

Hosted on Acast. See acast.com/privacy for more information.

Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV Edition of  e ViralHepatitis Review. The first part of this program presented an evidence-based expert commentary by  e ViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor...

In her  Expert Commentary , Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability. Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve o...

Dr. Paul Auwaerter discusses XBB and XBB.1.5 subvariants and the respiratory virus season. Topics: *Why XBB and XBB.1.5 subvariants are more transmissible than other subvariants, but less virulent *Effect of Paxlovid on hospitalization and mortality *Summary of the flu and RSV season *Deciding when to treat a COVID-19 patient  Post-test for CME/CE credit: https://covid19.dkbmed.com/multispeci...

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices?  These are some of the questions advanced practice nurse Dallas Ducar, CEO of Transh...

Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this e CysticFibrosis Review Special Edition: CF and Nutrition and HEMT.   The first part of this program presented an evidence-based...

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation? Which drug combinations are right? Where does the balance between side effects and adherence lie? These are so...

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients? Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post docto...

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?  Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vince...

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorbidities be identified?  Join us as we discuss...

Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic?  Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this  e MultipleSclerosis Review podcast.  Take our  post-test  to claim CME credits. T...

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 testing. Topics: *Why are we seeing prolonged antigen positive test results? *Do we know when someone is infectious? For how long? *Speculating on the cause of Paxlovid rebound  Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/7-28-22-episode/eval    Access our resource center, download webinar slide...

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 immunity. Topics: *Is COVID-19 here to stay? *Immunity evasiveness of Omicron BA.4 and BA.5 *Expectations for the fall and winter 2022 *Thoughts on upcoming booster reformulation *Should you get a booster now or wait?  Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/7-28-22-episode/eval    Access ou...

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated?    Join us in this  e MultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Jose...

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say?  Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleScleros...

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)? Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, as we discuss these questions...

What was it like for a frontline critical care pulmonologist at the very beginning of the COVID-19 epidemic? On the frontlines as the epidemic became pandemic? What’s it like today, with new variants and new in-patient and out-patient treatments? What are the key differences between then and now, what have we learned, and how can we be better prepared for next time?  Join us for this  e Pulmo...

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care?   Join us for this  e CysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affe...